This article is more than 5 years old. Information may no longer be current.
FDA approves Xience Nano for treatment of CAD
Click Here to Manage Email Alerts
The FDA has recently approved the Xience Nano everolimus-eluting stent for the treatment of small vessels among patients with coronary artery disease.
The approval was based on results of the SPIRIT Small Vessel trial that indicated very low late loss of 0.2 mm and a target lesion failure rate of 8.1% with use of the stent. The Xience Nano (Abbott), which features thin struts measuring 0.0032 inches, utilizes the same platform as the Xience V system and will provide a new option for physicians treating patients with vessels as small as 2.25 mm in diameter.
“The treatment of small vessels is often complex and associated with higher rates of complications compared to larger vessels,” Marco Costa, MD, PhD, director, Heart & Vascular Institute, University Hospitals, Case Medical Center in Cleveland, and principal investigator of the SPIRIT Small Vessel trial, said in a press release. “I am confident that the highly deliverable XIENCE Nano stent, with its thin struts and effective everolimus-eluting platform, will help physicians treat their patients who have coronary artery disease in small vessels.”
Disclosure: Dr. Costa reports having received consulting fees/honoraria from Abbott Vascular.
 |
Follow CardiologyToday.com on Twitter. |